Literature DB >> 6500769

Combined drug therapy--cholestyramine and compactin--for familial hypercholesterolemia.

A Yamamoto, T Yamamura, S Yokoyama, H Sudo, Y Matsuzawa.   

Abstract

Combined drug therapy with cholestyramine and compactin was found to be extremely effective against heterozygous cases of familial hypercholesterolemia. With a single drug regimen, compactin at a dosage of 15 mg/day produced a cholesterol reduction of 23% (70 mg/dl) in cases of combined hyperlipidemia, while twice the dosage (30 mg/day) was needed to produce a comparable effect with heterozygous familial hypercholesterolemia. When compaction was combined with cholestyramine (in a 4 g dose three times a day), the cholesterol-lowering effect of compactin was strongly improved with heterozygous familial hypercholesterolemia; half the dosage of compactin was enough to produce the additive effect compared with the effect produced by each single drug regimen.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6500769

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  1 in total

1.  RPR 101821, a new potent cholesterol-lowering agent: inhibition of squalene synthase and 7-dehydrocholesterol reductase.

Authors:  D Amin; R Z Rutledge; S J Needle; D J Hele; K Neuenswander; R C Bush; G E Bilder; M H Perrone
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-01       Impact factor: 3.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.